• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Oral Anticoagulants and Antiplatelet Agents in Atrial Fibrillation Patients with Concomitant Critical Limb Ischemia: A nationwide cohort study
ConclusionsDOAC was associated with a significantly lower risk of composite net-clinical-benefit outcome than either warfarin or APT in AF patients with concomitant CLI. Further prospective study is necessary to validate the findings in the future.
Source: Canadian Journal of Cardiology - February 19, 2020 Category: Cardiology Source Type: research

Dual-Antithrombotic Therapy With DOACs After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials
ConclusionsIn patients with AF and recent ACS or PCI, the use of dual-antithrombotic therapy with DOACs was associated with less major bleeding and less major bleeding or clinically relevant nonmajor bleeding compared with triple therapy. The use of dual therapy also showed nonsignificantly higher composite of death and ischemic events but no difference in mortality.RésuméContexteIl est difficile de choisir un traitement antithrombotique en cas de fibrillation auriculaire (FA) chez les patients ayant subi un syndrome coronarien aigu (SCA) ou une intervention coronarienne percutanée (ICP). Nous avons comparé les résult...
Source: Canadian Journal of Cardiology - December 24, 2019 Category: Cardiology Source Type: research

Dual antithrombotic therapy with DOACs after ACS or PCI in Atrial Fibrillation: A meta-analysis of Randomized Controlled Trials
ConclusionsIn patients with AF and recent ACS or PCI, the use of dual antithrombotic therapy with DOACs was associated with less major bleeding, and major bleeding or clinically relevant non-major bleeding, compared to triple therapy. The use of dual therapy also shows non-significantly higher composite of death/ischemic events but no difference in mortality.
Source: Canadian Journal of Cardiology - November 14, 2019 Category: Cardiology Source Type: research

Oral anticoagulation for stroke prevention in Canadian practice: Stroke Prevention and Rhythm Interventions in Atrial Fibrillation (SPRINT-AF) registry
Conclusions In this contemporary Canadian AF registry, the rate of guideline-concordant OAC use was high. About half of OAC-treated patients received NOAC agents. Patient- and physician-driven preferences such as side effect profile, perceived greater efficacy, and cost were strong determinants of NOAC over warfarin use. Teaser This is a cross-sectional, retrospective analysis of 936 patients with non-valvular atrial fibrillation enrolled from 106 practices in Canada between December 2012 and July 2013. We observed that the rate of guideline-concordant oral anticoagulation use was high (90%), with new direct oral anticoagu...
Source: Canadian Journal of Cardiology - May 2, 2015 Category: Cardiology Source Type: research